Fig. 3.
Combination with anti-CTLA-4 improves and prolongs bystander expansion following systemic IT. Mice (n = 3–4 mice/group) were treated with control (rIgG/PBS) or IT (40/2) with either hamster IgG (hmIgG) or anti-CTLA-4 (UC10) as per the regimen in 2A and evaluated for T cell phenotype and function on various time points post-therapy. a Representative histograms of CD44 expression (pregated on CD8) and NKG2D/CD25 expression (pregated on CD44high). b Percentages and c numbers of CD25-NKG2D+ bystander CD8+ T cells. d–f OT-I mice were immunized with OVA/IFA. Thirty days later, OT-I CD8 T cells were isolated and adoptively transferred into WT congenic C57BL/6 mice, which were subsequently treated (n = 2–3 mice/group) as described above. d Schema depicting experimental design. e Representative histograms of NKG2D and CD25 expression on CD45.2 + CD8 + Va2 + CD44high OT-I T cells. f Percentages and g numbers of CD25-NKG2D+ bystander-activated, adoptively transferred OT-I T cells post-treatment. Data are representative of 1–3 independent experiments. Statistical analysis was performed using one- or two-way ANOVA where appropriate with Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001